Assembly Biosciences Announces Pricing of $125 Million Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced the pricing of an underwritten public offering of 5,151,515 shares of its common stock to the public at $16.50 per share. In addition, and in lieu of common stock, Assembly is offering to a certain existing investor pre-funded warrants to purchase up to an aggregate of 2,424,242 shares of common stock at a purchase price of $16.499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The offering is expected to close on or about December 16, 2019, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds to Assembly from this offering are expected to be approximately $125 million, before deducting underwriting discounts and commissions and other offering expenses payable by Assembly. Assembly has granted the underwriters a 30-day option to purchase up to an additional 1,136,363 shares of common stock at the offering price, less the underwriting discounts and commissions. Assembly intends to use the net proceeds from the sale of the common stock to fund clinical trials, nonclinical studies, research and development and for general corporate purposes. 

Jefferies LLC, SVB Leerink LLC and William Blair & Company, L.L.C. are acting as joint bookrunning managers for the offering. Mizuho Securities USA LLC and Robert W. Baird & Co. Incorporated are acting as co-managers for the offering.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-222366), which was declared effective by the U.S. Securities and Exchange Commission (“SEC”) on January 10, 2018.  A final prospectus supplement relating to this offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and accompanying prospectuses may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at [phone], or by email at [e-mail]; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at [phone], ext. 6132, or by email at [e-mail]; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at [phone], or by email at [e-mail].